747 related articles for article (PubMed ID: 15553717)
1. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
2. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
3. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
4. [Successful treatment of huge peritoneal metastasis from duodenal gastrointestinal stromal tumor resistant for imatinib mesylate].
Sakakura C; Kumano T; Mizuta Y; Yamaoka N; Sagara Y; Hagiwara A; Otsuji E
Gan To Kagaku Ryoho; 2007 Nov; 34(12):2144-6. PubMed ID: 18219926
[TBL] [Abstract][Full Text] [Related]
5. [A patient with metastatic gastrointestinal stromal tumor who responded to STI571].
Terashima M; Abe K; Takeda Y; Saito K; Uesugi N; Kato K; Sato K; Maekawa T
Gan To Kagaku Ryoho; 2002 Apr; 29(4):607-10. PubMed ID: 11977548
[TBL] [Abstract][Full Text] [Related]
6. Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor.
Sawaki A; Ohashi K; Yamao K; Inada K; Shimizu Y; Matsuura A; Nakamura T; Suzuki T; Hara K; Okubo K; Ohno R
J Gastroenterol; 2003; 38(7):690-4. PubMed ID: 12898363
[TBL] [Abstract][Full Text] [Related]
7. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic targets in gastrointestinal stromal tumors].
Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
[TBL] [Abstract][Full Text] [Related]
9. Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case.
Ando Y; Tsunoda T; Beck Y; Takayama T; Tahara H
Surg Today; 2005; 35(2):157-60. PubMed ID: 15674500
[TBL] [Abstract][Full Text] [Related]
10. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
[TBL] [Abstract][Full Text] [Related]
11. [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location].
Catani M; De Milito R; Simi M
Chir Ital; 2005; 57(1):127-33. PubMed ID: 15832750
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients.
Sawaki A; Yamao K; Nakamura T; Suzuki T; Okubo K; Hara K; Kawai H; Yamamura Y; Ito S; Mochiduki Y; Ohno R
J Gastroenterol; 2004; 39(4):329-33. PubMed ID: 15168243
[TBL] [Abstract][Full Text] [Related]
13. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
14. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
[TBL] [Abstract][Full Text] [Related]
15. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
Shiba K; Matsumoto T; Hirota S
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
[TBL] [Abstract][Full Text] [Related]
16. [Imatinib mesylate STI571 therapy for five patients with advanced gastrointestinal stromal tumors].
Shen KT; Hou YY; Qin XY; Song LJ; Sujie A
Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Mar; 8(2):129-31. PubMed ID: 16155822
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
[TBL] [Abstract][Full Text] [Related]
18. [A patient with diffuse peritoneal metastases of GIST who was administered STI571].
Mukaide H; Hasuike Y; Takeda Y; Shin E; Mishima H; Nishisyou I; Tujinaka T; Kawahara K; Kurata A
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2329-32. PubMed ID: 12484066
[TBL] [Abstract][Full Text] [Related]
19. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
20. [A long-term survival case with multiple liver metastases from duodenal gastrointestinal stromal tumor that was drastically reduced by the treatment with imatinib].
Sakakura C; Miyagawa K; Fukuda K; Kin S; Nakase Y; Kuriu Y; Nakashima S; Yoshikawa T; Yamaoka N; Sagara Y; Hagiwara A; Yamagishi H
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1739-41. PubMed ID: 16315926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
